



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Kostenuik et al.

Serial No.: 09/843,221 #8

Filed: April 26, 2001

For: Modulators of Receptors for Parathyroid Hormone and Parathyroid Hormone-Related Protein

Docket No.: A-665B

ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821

Assistant Commissioner for Patents
 Washington, D.C. 20231


Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated January 15, 2002.

I hereby state that the substitute paper copy and the substitute computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same.

The sequence listing submitted herewith contains no new matter.

Respectfully submitted,



Robert B. Winter
 Attorney/Agent for Applicant(s)
 Registration No.: 34,458
 Phone: (805) 447-2425
 Date: February 27, 2002

Please send all future correspondence to:

U.S. Patent Operations/RBW
 Dept. 4300, M/S 27-4-A
 AMGEN INC.
 One Amgen Center Drive
 Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

*Express Mail® mail labeling number: EL198797791USDate of Deposit: February 27, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

S.L. ST. ANDREW

Printed Name

S. B. Anderson

Signature

03C0



03-01-02

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/843,221	04/26/2001	Paul Kostenuik	A-665B

21069
 AMGEN INCORPORATED
 MAIL STOP 27-4-A
 ONE AMGEN CENTER DRIVE
 THOUSAND OAKS, CA 91320-1799

CONFIRMATION NO. 8369

FORMALITIES LETTER



OC000000007311106

Date Mailed: 01/15/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE